15 results on '"Lappalainen, M"'
Search Results
2. Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021.
- Author
-
Vauhkonen H, Nguyen PT, Kant R, Plyusnin I, Erdin M, Kurkela S, Liimatainen H, Ikonen N, Blomqvist S, Liitsola K, Lindh E, Helve O, Jarva H, Loginov R, Palva A, Hannunen T, Hannula S, Parry M, Kauppi P, Vaheri A, Sironen T, Lappalainen M, Savolainen-Kopra C, Smura T, and Vapalahti O more...
- Subjects
- Finland epidemiology, Humans, COVID-19 epidemiology, SARS-CoV-2 genetics
- Abstract
Multiple introductions of SARS-COV-2 Omicron variant BA.1 and BA.1.1. lineages to Finland were detected in early December 2021. Within 3 weeks, Omicron overtook Delta as the most common variant in the capital region. Sequence analysis demonstrated the emergence and spread through community transmission of a large cluster of BA.1.1 virus. more...
- Published
- 2022
- Full Text
- View/download PDF
Catalog
3. Scent dogs in detection of COVID-19: triple-blinded randomised trial and operational real-life screening in airport setting.
- Author
-
Kantele A, Paajanen J, Turunen S, Pakkanen SH, Patjas A, Itkonen L, Heiskanen E, Lappalainen M, Desquilbet L, Vapalahti O, and Hielm-Björkman A
- Subjects
- Airports, Animals, Dogs, Humans, Odorants, COVID-19 diagnosis, SARS-CoV-2
- Abstract
Objective: To estimate scent dogs' diagnostic accuracy in identification of people infected with SARS-CoV-2 in comparison with reverse transcriptase polymerase chain reaction (RT-PCR). We conducted a randomised triple-blinded validation trial, and a real-life study at the Helsinki-Vantaa International Airport, Finland., Methods: Four dogs were trained to detect COVID-19 using skin swabs from individuals tested for SARS-CoV-2 by RT-PCR. Our controlled triple-blinded validation study comprised four identical sets of 420 parallel samples (from 114 individuals tested positive and 306 negative by RT-PCR), randomly presented to each dog over seven trial sessions. In a real-life setting the dogs screened skin swabs from 303 incoming passengers all concomitantly examined by nasal swab SARS-CoV-2 RT-PCR. Our main outcomes were variables of diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) for scent dog identification in comparison with RT-PCR., Results: Our validation experiments had an overall accuracy of 92% (95% CI 90% to 93%), a sensitivity of 92% (95% CI 89% to 94%) and a specificity of 91% (95% CI 89% to 93%) compared with RT-PCR. For our dogs, trained using the wild-type virus, performance was less accurate for the alpha variant (89% for confirmed wild-type vs 36% for alpha variant, OR 14.0, 95% CI 4.5 to 43.4). In the real-life setting, scent detection and RT-PCR matched 98.7% of the negative swabs. Scant airport prevalence (0.47%) did not allow sensitivity testing; our only SARS-CoV-2 positive swab was not identified (alpha variant). However, ad hoc analysis including predefined positive spike samples showed a total accuracy of 98% (95% CI 97% to 99%)., Conclusions: This large randomised controlled triple-blinded validation study with a precalculated sample size conducted at an international airport showed that trained scent dogs screen airport passenger samples with high accuracy. One of our findings highlights the importance of continuous retraining as new variants emerge. Using scent dogs may present a valuable approach for high-throughput, rapid screening of large numbers of people., Competing Interests: Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) more...
- Published
- 2022
- Full Text
- View/download PDF
4. Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection.
- Author
-
Ahava MJ, Kurkela S, Kuivanen S, Lappalainen M, Jarva H, and Jääskeläinen AJ
- Subjects
- Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Humans, Nucleocapsid, RNA, Viral, Sensitivity and Specificity, COVID-19 diagnosis, SARS-CoV-2
- Abstract
SARS-CoV-2 RNA can be detected in respiratory samples for weeks after onset of COVID-19 disease. Therefore, one of the diagnostic challenges of PCR positive cases is differentiating between acute COVID-19 disease and convalescent phase. The presence of SARS-CoV-2 nucleocapsid antigen in serum and plasma samples of COVID-19 patients has been demonstrated previously. Our study aimed to characterize the analytical specificity and sensitivity of an enzyme-linked immunosorbent assay (Salocor SARS-CoV-2 Antigen Quantitative Assay Kit© (Salofa Ltd, Salo, Finland)) for the detection of SARS-CoV-2 nucleocapsid antigen in serum, and to characterize the kinetics of antigenemia. The evaluation material included a negative serum panel of 155 samples, and 126 serum samples from patients with PCR-confirmed COVID-19. The specificity of the Salocor SARS-CoV-2 serum nucleocapsid antigen test was 98.0 %. In comparison with simultaneous positive PCR from upper respiratory tract (URT) specimens, the test sensitivity was 91.7 %. In a serum panel in which the earliest serum sample was collected two days before the collection of positive URT specimen, and the latest 48 days after (median 1 day post URT sample collection), the serum N antigen test sensitivity was 95.6 % within 14 days post onset of symptoms. The antigenemia resolved approximately two weeks after the onset of disease and diagnostic PCR. The combination of simultaneous SARS-CoV-2 antigen and antibody testing appeared to provide useful information for timing of COVID-19. Our results suggest that SARS-CoV-2 N-antigenemia may be used as a diagnostic marker in acute COVID-19., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.) more...
- Published
- 2022
- Full Text
- View/download PDF
5. Incidence Trends for SARS-CoV-2 Alpha and Beta Variants, Finland, Spring 2021.
- Author
-
Kant R, Nguyen PT, Blomqvist S, Erdin M, Alburkat H, Suvanto M, Zakham F, Salminen V, Olander V, Paloniemi M, Huhti L, Lehtinen S, Luukinen B, Jarva H, Kallio-Kokko H, Kurkela S, Lappalainen M, Liimatainen H, Hannula S, Halkilahti J, Ikonen J, Ikonen N, Helve O, Gunell M, Vuorinen T, Plyusnin I, Lindh E, Ellonen P, Sironen T, Savolainen-Kopra C, Smura T, and Vapalahti O more...
- Subjects
- Finland epidemiology, Humans, Incidence, Phylogeny, COVID-19, SARS-CoV-2
- Abstract
Severe acute respiratory syndrome coronavirus 2 Alpha and Beta variants became dominant in Finland in spring 2021 but had diminished by summer. We used phylogenetic clustering to identify sources of spreading. We found that outbreaks were mostly seeded by a few introductions, highlighting the importance of surveillance and prevention policies. more...
- Published
- 2021
- Full Text
- View/download PDF
6. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
- Author
-
Jalkanen P, Pasternack A, Maljanen S, Melén K, Kolehmainen P, Huttunen M, Lundberg R, Tripathi L, Khan H, Ritvos MA, Naves R, Haveri A, Österlund P, Kuivanen S, Jääskeläinen AJ, Kurkela S, Lappalainen M, Rantasärkkä K, Vuorinen T, Hytönen J, Waris M, Tauriainen S, Ritvos O, Kakkola L, and Julkunen I more...
- Subjects
- Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Humans, Immunoenzyme Techniques, Immunoglobulin A immunology, Immunoglobulin G immunology, Immunoglobulin M blood, Immunoglobulin M immunology, Neutralization Tests, Phosphoproteins immunology, SARS-CoV-2 immunology, Sensitivity and Specificity, COVID-19 diagnosis, COVID-19 Serological Testing methods, Coronavirus Nucleocapsid Proteins immunology, Immunoglobulin A blood, Immunoglobulin G blood, SARS-CoV-2 isolation & purification, Spike Glycoprotein, Coronavirus immunology
- Abstract
Background: Primary diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is based on detection of virus RNA in nasopharyngeal swab samples. In addition, analysis of humoral immunity against SARS-CoV-2 has an important role in viral diagnostics and seroprevalence estimates., Methods: We developed and optimized an enzyme immunoassays (EIA) using SARS-CoV-2 nucleoprotein (N), S1 and receptor binding domain (RBD) of the viral spike protein, and N proteins from SARS, Middle East respiratory syndrome (MERS), and 4 low-pathogenic human CoVs. Neutralizing antibody activity was compared with SARS-CoV-2 IgG, IgA, and IgM EIA results., Results: The sensitivity of EIA for detecting immune response in COVID-19 patients (n = 101) was 77% in the acute phase and 100% in the convalescent phase of SARS-CoV-2 infection when N and RBD were used as antigens in IgG and IgA specific EIAs. SARS-CoV-2 infection significantly increased humoral immune responses against the 229E and NL63 N proteins. S1 and RBD-based EIA results had a strong correlation with microneutralization test results., Conclusions: The data indicate a combination of SARS-CoV-2 S1 or RBD and N proteins and analysis of IgG and IgA immunoglobulin classes in sera provide an excellent basis for specific and sensitive serological diagnostics of COVID-19., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.) more...
- Published
- 2021
- Full Text
- View/download PDF
7. Sources of healthcare workers' COVID‑19 infections and related safety guidelines.
- Author
-
Oksanen LAH, Sanmark E, Oksanen SA, Anttila VJ, Paterno JJ, Lappalainen M, Lehtonen L, and Geneid A
- Subjects
- Adult, COVID-19 transmission, Cross-Sectional Studies, Female, Finland epidemiology, Humans, Male, Prospective Studies, COVID-19 epidemiology, Disease Transmission, Infectious prevention & control, Health Personnel, Personal Protective Equipment standards, SARS-CoV-2
- Abstract
Objectives: To evaluate the effectiveness of safety guidelines in the workplace, the authors analyzed the work-related exposure to SARS-CoV-2 and the source of COVID‑19 infections among healthcare workers (HCWs), together with the use of personal protective equipment (PPE)., Material and Methods: A cross-sectional prospective study was conducted in tertiary hospitals in the Uusimaa region, Finland, with 1072 volunteers being enrolled in the study from among the HCWs at the Helsinki University Hospital. Overall, 866 (80.8%) HCWs (including 588 nurses, 170 doctors, and 108 laboratory and medical imaging nurses) completed the questionnaire by July 15, 2020, with 52% of the participants taking care of COVID‑19 patients. The participants answered a structured questionnaire regarding their use of PPE, the ability to follow safety guidelines, exposure to COVID‑19, and the source of potential COVID‑19 infections. The participants with COVID‑19 symptoms were tested with the SARS-CoV-2 realtime polymerase chain reaction method. All infected participants were contacted, and their answers were confirmed regarding COVID‑19 exposure., Results: In total, 41 (4.7%) participants tested positive for SARS-CoV-2, with 22 (53.6%) of infections being confirmed or likely occupational, and 12 (29.3%) originating from colleagues. In 14 cases (63.6%), occupational infections occurred while using a surgical mask, and all infections originating from patients occurred while using a surgical mask or no mask at all. No occupational infections were found while using an FFP2/3 respirator and following aerosol precautions. The combined odds ratio for working at an intensive care unit, an emergency department, or a ward was 3.4 (95% CI: 1.2-9.2, p = 0.016)., Conclusions: A high infection rate was found among HCWs despite safety guidelines. Based on these findings, the authors recommend the use of FFP2/3 respirators in all patient contacts with confirmed or suspected COVID‑19, along with the use of universal masking, also in personnel rooms. Int J Occup Med Environ Health. 2021;34(2):239-49., (This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL license.) more...
- Published
- 2021
- Full Text
- View/download PDF
8. Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection.
- Author
-
Jääskeläinen AE, Ahava MJ, Jokela P, Szirovicza L, Pohjala S, Vapalahti O, Lappalainen M, Hepojoki J, and Kurkela S
- Subjects
- COVID-19 immunology, COVID-19 virology, COVID-19 Nucleic Acid Testing methods, COVID-19 Testing methods, Humans, Nasopharynx virology, Retrospective Studies, SARS-CoV-2 immunology, Sensitivity and Specificity, Antigens, Viral analysis, COVID-19 diagnosis, COVID-19 Serological Testing methods, SARS-CoV-2 isolation & purification
- Abstract
Introduction: The COVID-19 pandemic has led to high demand of diagnostic tools. Rapid antigen detection tests have been developed and many have received regulatory acceptance such as CE IVD or FDA markings. Their performance needs to be carefully assessed., Materials and Methods: 158 positive and 40 negative retrospective samples collected in saline and analyzed by a laboratory-developed RT-PCR test were used to evaluate Sofia (Quidel), Standard Q (SD Biosensor), and Panbio™ (Abbott) rapid antigen detection tests (RADTs). A subset of the specimens was subjected to virus culture., Results: The specificity of all RADTs was 100 % and the sensitivity and percent agreement was 80 % and 85 % for Sofia, 81 % and 85 % for Standard Q, and 83 % and 86 % for Panbio™, respectively. All three RADTs evaluated in this study reached a more than 90 % sensitivity for samples with a high viral load as estimated from the low Ct (Cycle threshold) values in the reference RT-PCR. Virus culture was successful in 80 % of specimens with a Ct value <25., Conclusions: As expected, the RADTs were less sensitive than RT-PCR. However, they benefit from the speed and ease of testing, and lower price as compared to RT-PCR. Repeated testing in appropriate settings may improve the overall performance., (Copyright © 2021 Elsevier B.V. All rights reserved.) more...
- Published
- 2021
- Full Text
- View/download PDF
9. Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA.
- Author
-
Mannonen L, Kallio-Kokko H, Loginov R, Jääskeläinen A, Jokela P, Antikainen J, Väre P, Kekäläinen E, Kurkela S, Jarva H, and Lappalainen M
- Subjects
- COVID-19 epidemiology, Humans, Nucleic Acid Amplification Techniques methods, COVID-19 virology, COVID-19 Testing methods, SARS-CoV-2 isolation & purification
- Abstract
Mitigation of the ongoing coronavirus disease 2019 (COVID-19) pandemic requires reliable and accessible laboratory diagnostic services. In this study, the performance of one laboratory-developed test (LDT) and two commercial tests, cobas SARS-CoV-2 (Roche) and Amplidiag COVID-19 (Mobidiag), were evaluated for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory specimens. A total of 183 specimens collected from suspected COVID-19 patients were studied with all three methods to compare their performance. In relation to the reference standard, which was established as the result obtained by two of the three studied methods, the positive percent agreement was highest for the cobas test (100%), followed by the Amplidiag test and the LDT (98.9%). The negative percent agreement was lowest for the cobas test (89.4%), followed by the Amplidiag test (98.8%), and the highest value was obtained for the LDT (100%). The dilution series of positive specimens, however, suggests significantly higher sensitivity for the cobas assay in comparison with the other two assays, and the low negative percent agreement value may be due to the same reason. In general, all tested assays performed adequately. Clinical laboratories need to be prepared for uninterrupted high-throughput testing during the coming months to mitigate the pandemic. To ensure no interruption, it is critical that clinical laboratories maintain several simultaneous platforms in their SARS-CoV-2 nucleic acid testing., (Copyright © 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.) more...
- Published
- 2021
- Full Text
- View/download PDF
10. Laboratory-based surveillance of COVID-19 in the Greater Helsinki area, Finland, February-June 2020.
- Author
-
Jarva H, Lappalainen M, Luomala O, Jokela P, Jääskeläinen AE, Jääskeläinen AJ, Kallio-Kokko H, Kekäläinen E, Mannonen L, Soini H, Suuronen S, Toivonen A, Savolainen-Kopra C, Loginov R, and Kurkela S
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, COVID-19 virology, Child, Child, Preschool, Epidemiological Monitoring, Female, Finland epidemiology, Humans, Infant, Laboratories, Hospital, Male, Middle Aged, Registries, SARS-CoV-2 genetics, Sex Factors, Young Adult, COVID-19 epidemiology, COVID-19 Testing statistics & numerical data, SARS-CoV-2 isolation & purification
- Abstract
Objectives: The aim was to characterise age- and sex-specific severe acute respiratory syndrome coronavirus disease-2 (SARS-CoV-2) RT-PCR sampling frequency and positivity rate in Greater Helsinki area in Finland during February-June 2020. We also describe the laboratory capacity building for these diagnostics., Methods: Laboratory registry data for altogether 80,791 specimens from 70,517 individuals was analysed. The data included the date of sampling, sex, age and the SARS-CoV-2 RT-PCR test result on specimens collected between 1 February and 15 June 2020., Results: Altogether, 4057/80,791 (5.0%) of the specimens were positive and 3915/70,517 (5.6%) of the individuals were found positive. In all, 37% of specimens were from male and 67% from female subjects. While the number of positive cases was similar in male and female subjects, the positivity rate was significantly higher in male subjects: 7.5% of male and 4.4% of female subjects tested positive. The highest incidence/100,000 was observed in those aged ≥80 years. The proportion of young adults in positive cases increased in late May 2020. Large dips in testing frequency were observed during every weekend and also during public holidays., Conclusions: Our data suggest that men pursue SARS-CoV-2 testing less frequently than women. Consequently, a subset of coronavirus disease-2019 infections in men may have gone undetected. People sought testing less frequently on weekends and public holidays, and this may also lead to missing of positive cases. The proportion of young adults in positive cases increased towards the end of the study period, which may suggest their returning back to social behaviour with an increased risk of infection., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.) more...
- Published
- 2021
- Full Text
- View/download PDF
11. Saliva-based testing for diagnosis of SARS-CoV-2 infection: A meta-analysis.
- Author
-
Kivelä JM, Jarva H, Lappalainen M, and Kurkela S
- Subjects
- Adult, Humans, Molecular Diagnostic Techniques, Sensitivity and Specificity, Specimen Handling, COVID-19 diagnosis, COVID-19 Testing methods, SARS-CoV-2 isolation & purification, Saliva virology
- Published
- 2021
- Full Text
- View/download PDF
12. SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors.
- Author
-
Kantele A, Lääveri T, Kareinen L, Pakkanen SH, Blomgren K, Mero S, Patjas A, Virtanen J, Uusitalo R, Lappalainen M, Järvinen A, Kurkela S, Jääskeläinen AJ, Vapalahti O, and Sironen T
- Subjects
- Adult, Antibodies, Viral blood, Asymptomatic Infections epidemiology, COVID-19 diagnosis, COVID-19 pathology, COVID-19 prevention & control, Female, Finland epidemiology, Hospitals, University, Humans, Male, Middle Aged, Risk Factors, SARS-CoV-2 isolation & purification, Seroepidemiologic Studies, COVID-19 epidemiology, Health Personnel statistics & numerical data, SARS-CoV-2 immunology
- Abstract
Background: Exposure, risks and immunity of healthcare workers (HCWs), a vital resource during the SARS-CoV-2 pandemic, warrant special attention., Methods: HCWs at Helsinki University Hospital, Finland, filled in questionnaires and provided serum samples for SARS-CoV-2-specific antibody screening by Euroimmun IgG assay in March-April 2020. Positive/equivocal findings were confirmed by Abbott and microneutralization tests. Positivity by two of the three assays or RT-PCR indicated a Covid-19 case (CoV+)., Results: The rate of CoV(+) was 3.3% (36/1095) and seropositivity 3.0% (33/1095). CoV(+) was associated with contact with a known Covid-19 case, and working on a Covid-19-dedicated ward or one with cases among staff. The rate in the Covid-19-dedicated ICU was negligible. Smoking and age <55 years were associated with decreased risk. CoV(+) was strongly associated with ageusia, anosmia, myalgia, fatigue, fever, and chest pressure. Seropositivity was recorded for 89.3% of those with prior documented RT-PCR-positivity and 2.4% of those RT-PCR-negative. The rate of previously unidentified cases was 0.7% (8/1067) and asymptomatic ones 0% (0/36)., Conclusion: Undiagnosed and asymptomatic cases among HCWs proved rare. An increased risk was associated with Covid-19-dedicated wards. Particularly high rates were seen for wards with liberal HCW-HCW contacts, highlighting the importance of social distancing also among HCWs., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.) more...
- Published
- 2021
- Full Text
- View/download PDF
13. Low incidence of severe bacterial infections in hospitalised patients with COVID-19: A population-based registry study.
- Author
-
Ahava, M. J., Kortela, E., Forsblom, E., Pätäri-Sampo, A., Friberg, N., Meretoja, A., Kivivuori, S.-M., Lappalainen, M., Kurkela, S., Järvinen, A., and Jarva, H.
- Subjects
COVID-19 ,BACTERIAL diseases ,NOSOCOMIAL infections ,COVID-19 treatment ,GRAM-positive bacteria ,BACTERIAL meningitis - Abstract
Bacterial infections complicating COVID-19 are rare but present a challenging clinical entity. The aim of this study was to evaluate the incidence, aetiology and outcome of severe laboratory-verified bacterial infections in hospitalised patients with COVID-19. All laboratory-confirmed patients with COVID-19 admitted to specialised healthcare hospitals in the Capital Province of Finland during the first wave of COVID-19 between 27 February and 21 June 2020 were retrospectively studied. We gathered the blood and respiratory tract culture reports of these patients and analysed their association with 90-day case-fatality using multivariable regression analysis. A severe bacterial infection was diagnosed in 40/585 (6.8%) patients with COVID-19. The range of bacteria was diverse, and the most common bacterial findings in respiratory samples were gram-negative, and in blood cultures gram-positive bacteria. Patients with severe bacterial infection had longer hospital stay (mean 31; SD 20 days) compared to patients without (mean 9; SD 9 days; p < 0.001). Case-fatality was higher with bacterial infection (15% vs 11%), but the difference was not statistically significant (OR 1.38 CI95% 0.56–3.41). Severe bacterial infection complicating COVID-19 was a rare occurrence in our cohort. Our results are in line with the current understanding that antibiotic treatment for hospitalised COVID-19 patients should only be reserved for situations where a bacterial infection is strongly suspected. The ever-evolving landscape of the pandemic and recent advances in immunomodulatory treatment of COVID-19 patients underline the need for continuous vigilance concerning the possibility and frequency of nosocomial bacterial infections. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
14. COVID-19 cases in spectators returning to Finland from UEFA Euro 2020 matches in Saint Petersburg.
- Author
-
Sarvikivi, E., Salminen, M., Savolainen-Kopra, C., Ikonen, N., Kontio, M., Isosomppi, S., Jamanca, S., Hannila-Handelberg, T., Vapalahti, O., Smura, T., Lappalainen, M., and Helve, O.
- Abstract
UEFA Euro 2020 tournament was scheduled to take place in 2020, but due to the coronavirus disease 2019 (COVID-19) pandemic was rescheduled to start on 11 June 2021. Approximately 4500 Finnish spectators participated, travelling between Finland and Russia during the period of 16 to 30 June to attend matches played on 16 and 21 June. A total of 419 persons returning from Russia or with a connection to Russia were detected positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of the 321 sequenced samples 303 turned out to be of the Delta variant. None of these cases was hospitalised. In the following weeks findings of the Delta variant increased rapidly. Thus, EURO 2020 travel-related imported cases likely facilitated this rapid surge of Delta variant, but this impact would likely have been seen with the typical increase in the number of travellers entering Finland later in the summer. [ABSTRACT FROM AUTHOR] more...
- Published
- 2022
- Full Text
- View/download PDF
15. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation.
- Author
-
Jääskeläinen, AJ, Kuivanen, S, Kekäläinen, E, Ahava, MJ, Loginov, R, Kallio-Kokko, H, Vapalahti, O, Jarva, H, Kurkela, S, and Lappalainen, M
- Subjects
- *
SARS-CoV-2 , *IMMUNOGLOBULIN M , *COVID-19 pandemic , *VIRUS diseases , *COVID-19 , *SERODIAGNOSIS - Abstract
• Microneutralisation test (MNT) was carried out for 62 COVID-19 patients. • Results from six commercial SARS-CoV-2 immunoassays were compared to MNT. • Performance of different immunoassays were variable. There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We compared the performance of six commercial immunoassays for the detection of SARS-COV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-COV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-COV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-COV-2 IgG/IgM (CE marked)] with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel (N=70) included sera from PCR confirmed COVID-19 patients, and the negative panel (N=81) included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies.The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1 %/80.5 % (Abbott Architect SARS-CoV-2 IgG), 94.9 %/43.8 % (Diasorin Liaison SARS-CoV-2 IgG; RUO), 68.3 %/87.8 % (Euroimmun SARS-CoV-2 IgA), 86.6 %/70.7 % (Euroimmun SARS-CoV-2 IgG), 74.4 %/56.1 % (Acro 2019-nCoV IgG), 69.5 %/46.3 % (Acro 2019-nCoV IgM), 97.5 %/71.9 % (Xiamen Biotime SARS-CoV-2 IgG), and 88.8 %/81.3 % (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS- CoV-2 serodiagnostics. [ABSTRACT FROM AUTHOR] more...
- Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.